Determination of the enantiomer and positional isomer impurities in Atomoxetine hydrochloride (cas 82248-59-7) with liquid chromatography using polysaccharide chiral stationary phases
-
Add time:07/19/2019 Source:sciencedirect.com
A normal-phase isocratic chiral liquid chromatographic method has been developed and validated for Atomoxetine hydrochloride (cas 82248-59-7). In addition to the S-enantiomer of atomoxetine, the conditions separate both para and meta positional isomers and the phenyl des-methyl analog. Method development strategies included (a) evaluation of polysaccharide-based chiral stationary phases with nonaqueous mobile phases, (b) the use of an octyl stationary phase with a sulfated-β-cyclodextrin mobile phase additive, and (c) capillary electrophoresis using a single isomer heptakis-6-sulfato-β-cyclodextrin modifier. All three approaches yielded acceptable conditions for the separation of atomoxetine from related molecules with the former fully validated and the latter two held as alternatives if needed. The final method conditions employing a Chiralcel OD-H column and mobile phase of hexane/IPA/DEA/TFA (85/15/0.15/0.2, v/v/v/v) at 1.0 mL/min have been fully validated with acceptable specificity, linearity, accuracy, repeatability, intermediate precision and quantitation limit.
We also recommend Trading Suppliers and Manufacturers of Atomoxetine hydrochloride (cas 82248-59-7). Pls Click Website Link as below: cas 82248-59-7 suppliers
Prev:Atomoxetine, a selective norepinephrine reuptake inhibitor, improves short-term histological outcomes after hypoxic-ischemic brain injury in the neonatal male rat
Next:Atomoxetine hydrochloride (cas 82248-59-7) in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor ‘knockout’ mice07/24/2019
- Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial07/23/2019
- Conditioned place preference studies with atomoxetine in an animal model of ADHD: Effects of previous atomoxetine treatment07/22/2019
- Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson’s disease07/20/2019
- Atomoxetine hydrochloride (cas 82248-59-7) in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study07/21/2019
- Atomoxetine, a selective norepinephrine reuptake inhibitor, improves short-term histological outcomes after hypoxic-ischemic brain injury in the neonatal male rat07/18/2019
- Atomoxetine prevents working memory loss in hyperactive rats, mediating plastic changes in prefrontal cortex pyramidal neurons07/17/2019
- Atomoxetine hydrochloride (cas 82248-59-7) for the treatment of attention-deficit/hyperactivity disorder07/16/2019
- A quality by design approach to impurity method development for Atomoxetine hydrochloride (cas 82248-59-7) (LY139603)07/15/2019
-
Health and Chemical more >


